
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2022

Commission File Number 001-38370

CollPlant Biotechnologies Ltd.
(Exact name of registrant as specified in its charter)

4 Oppenheimer St, Weizmann Science Park
Rehovot 7670104, Israel
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐

CollPlant Biotechnologies Ltd. has posted to its website an updated corporate presentation. A copy of the presentation is furnished with this Report of Foreign Private Issuer on Form 6-K as [Exhibit 99.1](#) and is incorporated herein by reference.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

COLLPLANT BIOTECHNOLOGIES LTD.

Date: November 17, 2022

By: /s/ Eran Rotem

Name: Eran Rotem

Title: Deputy CEO and Chief Financial Officer

2

CollPlant Overview



CollPlant
Biotechnologies

Pioneering
Regenerative
Medicine

November 2022

Safe harbor statement

Certain statements in this presentation constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and are expected to be affected by a variety of risks and factors that are beyond our control. Risks and uncertainties for our company include, but are not limited to: the Company's history of significant losses and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based Bioink and products for medical aesthetics; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based Bioink and medical aesthetics products including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected

capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. Many of these factors that will determine actual results are beyond our ability to control or predict. For a discussion of the factors that may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied in such forward-looking statements, see the "Risk Factors" section of included in our most recently filed Annual Report on Form 20-F. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

The statements made in this presentation speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs to change. Unless otherwise required by applicable securities laws, we do not intend, nor do we undertake any obligation, to update or revise any forward-looking statements contained in this presentation to reflect subsequent information, events, results or circumstances or otherwise. While we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.

CollPlant – Unlocking the Regenerative Potential of rhCollagen



Regenerative and Aesthetic Medicine Company

Developing innovative technologies and products for tissue regeneration and organ manufacturing, to help people live longer and better



Proprietary Plant-based Technology Platform

Only commercially viable solution for mass production of rhCollagen



Collaboration Agreements with Industry Leaders

- AbbVie (ABBV)- Worldwide exclusive agreement for dermal and soft tissue fillers. Up to \$103mm in payments plus royalties.
- TAU and Sheba Medical Center – Co-development of a 3D bioprinted gut-on-a-chip for drug discovery and personalized medicine.



Well Capitalized


\$36M in cash
Zero debt
(June 30, 2022)

3



Plant-based platform produces human collagen in mass-scale


Expressing 5 human genes



4



Large scale human collagen produced in tobacco plants



5

CollPlant
Transforming Regenerative Medicine

rhCollagen- The ideal building block for regenerative medicine

Clear advantages over tissue-extracted collagen



Better bio-functionality



Superior homogeneity



Improved safety and greater purity

6

Plant-derived




Animal Extracted



Cell binding domains

CollPlant
Revolutionizing Tissue Repair

Product Pipeline



Dermal/Soft Tissue Fillers

In collaboration with **Allergan**
an AbbVie company



Dermal fillers market overview



~2.6 M

HA procedures
in 2020 in the US¹



\$5B, 9.6% CAGR


Global dermal filler market,
2021, CAGR 2022-2028²



\$100-\$250/unit

Cost per syringe³

2020 Procedure breakdown, U.S (by material)¹



9

- <https://www.plasticsurgery.org/documents/News/Statistics/2020/plastic-surgery-statistics-full-report-2020.pdf>
- <https://www.gminsights.com/industry-analysis/dermal-filler-market>
- <https://www.medicalspare.com/juvederm-hydrate>, <https://www.medicalspare.com/buy-juvederm-ultra-plus-xc>



Collaboration agreement with AbbVie

Agreement highlights:



A worldwide exclusive development and commercialization agreement for dermal and soft tissue fillers for the medical aesthetics market



Combines CollPlant's proprietary rhCollagen technology and AbbVie's technology



Right of first negotiation for exclusive rights to use the rhCollagen for the commercialization and sale of an injectable breast implant and photocurable dermal filler products

Financial highlights:



Up to \$103M in potential payments, including:

- \$14M upfront payment
- Up to \$89M milestones and option payments



Royalties on products sales



CollPlant will manufacture and sell to AbbVie the rhCollagen used in the products


10



rhCollagen-based photocurable regenerative dermal filler*

key attributes

**Easy injection
(30G needle)**



Injection

**Sculpting before
curing**




Sculpting

**Optimized post
curing stiffness**



Photocuring in-situ

**Good tissue
retention**



Tissue regeneration

**AbbVie's Option Product*

11 <http://collplant.com/products/photocurable-dermal-filler-animation-video/>

CollPlant
Tissue Regeneration Institute

Breast Reconstruction / Augmentation



Breast implants market overview

Current breast reconstruction is based on synthetic breast implantation, free flap surgery/autologous fat tissue transfer - all of which replace tissue rather than regenerate it.



\$2.5B Market
worldwide (2021)¹




\$ 5-10K Cost
per full procedure in US²



~2,200,000
Breast implant procedures WW (2020)³
~400,000 in US (2020)⁴



FDA alert: Patients with breast implants have an increased risk of developing breast implant Associated-Anaplastic Large Cell Lymphoma (Feb 2019)⁵




- <https://www.imarigroup.com/breast-implant-market>
- <https://www.webmd.com/beauty/cosmetic-procedures-breast-augmentation#1>
- https://www.isaps.org/wp-content/uploads/2022/01/ISAPS-Global-Survey_2020.pdf
- <https://www.plasticsurgery.org/documents/News/Statistics/2020/plastic-surgery-statistics-full-report-2020.pdf>
- <https://www.fda.gov/medical-devices/letters-health-care-providers/breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl-letter-health-care-providers>

CollPlant's 3D bioprinted regenerative breast implants for aesthetic and reconstructive procedures



Breast scaffold bioprinting



rhCollagen + ECM components



Implantation and vascularization



Implant degrades over time and replaced by newly formed tissue

15 * Pig study initiated in Q2 2022, expected to conclude in six months



Regenerative Tissue Matrix (RTM)



Provide extra coverage, direct-to-implant reconstruction and superior cosmetic results



US: mostly human-sourced (93%)
EU: mostly animal-sourced



Used in 61% of U.S. breast reconstruction surgeries



Breast reconstruction procedures using ADMS /yr (US): **60K**



Market potential (US) **\$600Mn**

Surgical matrixes derived from cadavers and animals are associated with high costs, supply shortage and batch-to-batch variability

rhCollagen-based regenerative tissue matrix



16



Gut-on-a-chip



Inflammatory bowel diseases

Inflammatory bowel diseases, which include ulcerative colitis and crone's disease, are characterized by chronic inflammation, a relapsing and remitting clinical course and lifelong treatment.



>6 Mn patients*
worldwide



No cure



Individualized
treatment for each patient,
some fail to respond



Limited models
In predicting therapeutic
response, resulting in exposure to
unjustified drugs and delay in
treatment

There is a need for novel personalized platforms to improve therapeutic choices and patient outcome

*[https://www.thelancet.com/journals/%20langas/article/PIIS2468-1253\(19\)30358-9/fulltext](https://www.thelancet.com/journals/%20langas/article/PIIS2468-1253(19)30358-9/fulltext)

rhCollagen-based 3D bioprinted gut-on-a-chip for drug discovery and personalized medicine



Co-development agreement with
Tel-Aviv University and Sheba
Medical Center



Model designed to accurately
mimic the human intestine tissue
structure and function



Patient specific cells to enable
screening of multiple drugs and
identification of the most effective
personalized therapeutic response

Agreement terms (Nov 2022)


CollPlant receives exclusive license for development, manufacturing and commercializing of the product
Tel Aviv University and Sheba will receive royalties on product sales

19

3D Bioprinted Tissues and Organs





3D bioprinting represents a wide range of development opportunities



21

rhCollagen-based BioInks enable high resolution printing of elastic scaffolds



22

rhCollagen BioInk compositions in development



Collink.3D – rhCollagen-bioink platform for biofabrication



Animal-free, excellent
safety profile



Optimal rheology at
room temperature



Supports high viability
of different cell types



Biocompatible, non
immunogenic

In the market:



Coming soon:



Our Partners

abbvie

Development and
commercialization agreement

CELLINK
A BICO COMPANY

Collaboration
agreement

SHEBA
Tel HaShomer
City of Health

TEL AVIV UNIVERSITY

Joint development
agreement

3D SYSTEMS

Joint Development
Agreement

armi
Advanced Regenerative
Manufacturing Institute

Scalable manufacturing of
tissue engineered products

ReMDO

Universal BioInk



Industry committee

STEMCELL
TECHNOLOGIES

Supply
agreement

25

Experienced management team



Yehiel Tal
CEO
Regentis
Biomaterials
ProChon Biotech
Kulicke & Soffa
Industries



Eran Rotem
Deputy CEO & CFO
Tefron, CFO (NYSE, TASE)
Healthcare Tech., CFO
(NASDAQ) & Gamida
E&Y



Elana Gazal, PhD
VP R&D
Neuroderm (now
Mitsubishi Tanabe)
Waters IS
Foamix (now Wyne)
Beckman Coulter



Michal Roytman
VP Sales & Marketing
Ocon Medical
Neuroderm (now
Mitsubishi Tanabe)
Neurim Pharmaceuticals
Frutarom (now IFF)



Ilana Belzer, PhD
COO
BioHarvest
Procognia Ltd.
Omix
Biopharmaceuticals
Interpharm



**Philippe
Bensimon, PharmD**
VP RA/QA/CA
Maquet Getinge
3M Medical



**Hadas Dreier-
Horowitz**
VP HR
Elbit
Teva Pharmaceuticals
Mul-T-Lock

26

CollPlant investment thesis



Only commercially viable technology currently available that can produce truly human collagen



Multi-billion dollar markets: innovative rhCollagen products initially aimed at 3D bioprinting and medical aesthetics



Broadly applicable technology: Ideal building block/scaffolding molecule for regenerative medicine



Strategic agreement with AbbVie



Clinically validated technology



Proven management team

27



Thank you



CollPlant
Biotechnologies

Pioneering
Regenerative
Medicine